3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
8
Terminated
3
Unknown
2
Recruiting
2
Active not recruiting
2
Withdrawn
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
93
Gynecologic
77
Breast
65
Thoracic
47
Head & Neck
16
Other solid neoplasm
7
Genitourinary
6
Tumor-Agnostic
4
Sarcoma
4
CNS
3
Other hematologic neoplasm
2
Lymphoid
2
Endocrine
2
Dermatologic
2
Other neoplasm
1
Other
1
Conditions
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Recurrence
1
Adrenocortical Carcinoma
1
Interventions
lutetium Lu 177 dotatate
6
Everolimus
6
lanreotide
5
anlotinib
5
Temozolomide
5
Injections
4
Dexmedetomidine
4
Cisplatin
4
surufatinib
3
Thyrotropin Alfa
3
Sodium Chloride
3
Saline Solution
3
Blood Specimen Collection
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
(177)Lu-DOTA-EB-TATE
3
sintilimab
2
penpulimab
2
cabozantinib
2
Surgical Procedures, Operative
2
Sorafenib
2
Rosiglitazone
2
Radiotherapy
2
Radiofrequency Ablation
2
Positron Emission Tomography Computed Tomography
2
Paclitaxel
2
Nivolumab
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Metformin
2
Magnetic Resonance Spectroscopy
2
Lymph Node Excision
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
Paclitaxel
×
Endocrine
×
Clear all
NCT00786552
2011-01-20
Panthera
University Hospital Schleswig-Holstein
Phase 2
Unknown
47 enrolled
NCT00786110
2009-02-24
PAXO
University of Turin, Italy
Phase 2
Unknown
30 enrolled